XARELTO®: Stroke risk reduction in nonvalvular atrial fibrillation (NVAF)

WHY WOULDN'T YOU CHOOSE A NOAC WITH PROVEN ONCE-DAILY, 24-HOUR STROKE REDUCTION IN PATIENTS WITH ELEVATED RISK?

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*Taken with evening meal.

Patients were considered at an increased risk for stroke if they had a higher CHADS2 score (range 1-6). Patients in ROCKET AF had a mean CHADS2 score of 3.5.

NOAC = non-vitamin K antagonist oral anticoagulant.